BioCentury | May 4, 2020
Product Development

Investors see little value in remaining Newron programs following Rett syndrome failure

The failure of Newron’s sarizotan in Rett syndrome leaves the company with two pipeline programs, but its valuation is now trading near its cash position -- a sign that investors see little value in what...
BC Innovations | Oct 31, 2018
Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies suggest M1 muscarinic receptor (CHRM1)-based chemogenetic inhibition of the prelimbic paraventricular thalamic nucleus pathway could help treat cocaine addiction. The system for chemogenetically inhibiting the pathway is initiated by bilateral injection...
BC Innovations | Aug 1, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method enabling BBB entry, and temporal and cell type-specific control of chemogenetic therapies could be used to develop treatments for CNS diseases. The method, dubbed acoustically targeted chemogenetics (ATAC), involves three...
BC Innovations | Jul 31, 2018
Translation in Brief

ATAC of the DREADDs

Scientists from the California Institute of Technology have combined ultrasound waves with gene and drug therapies to selectively and non-invasively control neural circuits. The approach could be used to treat neurologic and psychiatric diseases and...
BC Extra | May 25, 2018
Preclinical News

Activating astrocytes to enhance memory

In a paper published in Cell , researchers at The Hebrew University of Jerusalem showed that activating astrocytes in the hippocampus, rather than direct neuronal activation, could improve memory. Previous studies have shown that astrocytes modulate...
BC Innovations | Dec 6, 2016
Distillery Techniques

Imaging

TECHNOLOGY: PET A clozapine-based PET imaging agent that binds DREADD-expressing neurons could help monitor the engraftment of neuronal transplants for neurological diseases. The PET agent consisted of 11 C radionuclide-labeled clozapine-N-oxide, which has a binding...
BioCentury | Apr 11, 2016
Regulation

Tolerable uncertainty

Acadia Pharmaceuticals Inc. may have found a sensitive endpoint for Nuplazid pimavanserin in a condition lacking good measures by adapting a validated but broader scale. Although an FDA advisory committee was uncertain how much real-world...
BC Innovations | Mar 3, 2016
Distillery Therapeutics

Therapeutics: An undetermined target

Neurology INDICATION: Parkinson's disease (PD) Mouse studies suggest inhibiting thalamostriatal terminal activity could help treat Parkinson's disease (PD). Levels of thalamic input to indirect-pathway and direct-pathway medium spiny neurons (MSNs) were higher and lower, respectively,...
BC Week In Review | Jul 13, 2015
Company News

Oncothyreon, Braeburn deal

Oncothyreon granted Braeburn rights to develop and commercialize ATI-9242, a next-generation atypical antipsychotic agent modeled on clozapine that has completed a Phase I trial to treat schizophrenia. Braeburn plans to develop ATI-9242 into a long-acting...
BC Week In Review | Feb 24, 2014
Company News

Jazz Pharmaceuticals sales and marketing update

Jazz launched Versacloz clozapine in the U.S. to treat severely ill treatment-resistant schizophrenia patients or those at risk of recurrent suicidal behavior with schizophrenia or schizoaffective disorder. Versacloz has a wholesale acquisition cost of $734.14...
Items per page:
1 - 10 of 71